About Us

Paramita Therapeutics, Inc. (Paramita) is a preclinical-stage biotech company exploring the full potential of dual-targeted small molecule multivalent drug conjugation (MDC) strategies with companion diagnostics to treat cancer.  Paramita was founded in late 2018 by Dr. Sang Van, biotech entrepreneur, and Dr. Jack Bui, a professor at University of California, San Diego.

Paramita has developed a new therapeutic MDC platform that is capable of delivering a small molecule drug as a prodrug to tumor cells and delivering a viral peptide as a cancer vaccine to dendritic cells without additive toxicity to the patient.  MDC works like a “guided missile” with enhancement of binding affinity (avidity) and specificity via multivalency. Paramita has demonstrated that dual MDC targeting of surface cancer molecules like prostate-specific membrane antigen (PSMA) and folate-receptor (FR) improves antitumor efficacy.